JPRN-jRCT2080222779已完成3 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 493 人开始时间: 2015年3月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 493
研究概览
简要总结
In primary efficacy analysis for the primary endpoint (MMRM) of change from baseline in MADRS total score after 8 weeks of treatment, the differences were statistically significant in both vortioxetine 10 and 20 mg groups compared with the placebo group. No remarkable safety concerns were observed, and tolerability was favorable during the 8 weeks of treatment with vortioxetine 10 and 20 mg.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1. In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.
- •2. The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
- •3. The participant suffers from recurrent MDD as the primary diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.3x).
- •4. The participant is a man or a woman aged 20 to 75 years (both inclusive) at the time of informed consent.
- •5. The reported duration of the current major depressive episode is 3 to 12 months (both inclusive) at the start of screening period.
- •6. The participant has a MADRS total score >=26, Hamilton Depression Rating Scale (HAM-D17) total score >=18, and Clinical global impression scale-Severity (CGI-S) score >=4 at the start of screening period, at the start of placebo lead-in period and at the start of double-blind treatment period.
- •7. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to the end of the follow-up period.
排除标准
- •1. The participant has any following current or past history of psychiatric disorder and/or neurological disorder:
- •- Any current psychiatric disorder other than MDD as defined by DSM-IV-TR (To be assessed by Mini International Neuropsychiatric Interview: MINI). A participant who exhibits symptoms of anxiety is eligible unless the participant fulfills the diagnostic criteria for a current anxiety disorder per DSM-IV-TR.
- •- Current diagnosis or history of manic, mixed or hypomanic episode, MDD with psychotic features, schizophrenia or any other psychotic disorder (including substance-related mental disorders, or mental disorders due to a general medical condition) as defined by DSM-IV-TR.
- •- Current diagnosis or history of any substance-related disorder (except nicotine and caffeine-related disorders) as defined by DSM-IV-TR.
- •- The participant with a positive urine drug screening result at the start of screening period or the start of placebo lead-in period. In case that a participant showed positive test result at the start of screening period because the test was conducted before washout of pretreatment drug, the participant is eligible as long as he/she shows negative result at the start of placebo lead-in period.
- •- Presence or history of any clinically significant neurological disorder (including epilepsy).
- •- Any neurodegenerative disorder (e.g. Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease).
- •- Any DSM-IV-TR axis II disorder.
- •2. The participant has the current or previous major depressive episode which was considered by the investigator or sub-investigator to have been resistant to 2 or more adequate antidepressants treatments of at least 6 weeks duration each at sufficient doses.
- •3. The participant has received any augmentation therapy (e.g. lithium, T3/T4, lamotrigine, sodium valproate, carbamazepine, additional atypical antipsychotic, or concomitant use of other antidepressant, etc.) for the current major depressive episode.
- •4. In the opinion of the investigator or sub-investigator, the participant has experienced significant number of major depressive episodes in the past, and is suspected of disease other than MDD.
- •5. In the opinion of the investigator or sub-investigator, the participant has experienced the first major depressive episode at his/her young age, and is suspected of disease other than MDD.
- •6. The participant has a MADRS total score at the start of double-blind treatment period that has improved or aggravated by 25% or more from the score at the start of placebo lead-in period.
- •7. The participant is significantly non-compliant with the study drug in the placebo lead-in period; e.g., not taking the study drug for 6 or more consecutive days.
- •8. The participant has received electroconvulsive therapy, vagus nerve stimulation, or repetitive transcranial magnetic stimulation therapy within 6 months prior to the screening period, or plans to initiate such therapy during the study.
- •9. The participant is receiving cognitive-behavioral therapy or psychotherapy at the time of informed consent, or plans to initiate such therapy during the study.
- •10. The participant is at significant risk of suicide or has a score>=5 on Item 10 (suicidal thoughts) of the MADRS at the start of screening period, at the start of placebo lead-in period or at the start of double-blind treatment period, or has attempted suicide within 6 months prior to the start of screening period.
- •11. The participant has experience
研究者
相似试验
已完成
2 期
A Study of Brexpiprazole in Patients With Major Depressive DisorderMajor depressive disorderJPRN-jRCT2080223986Otsuka Pharmaceutical Co., Ltd.740
已完成
2 期
A Phase 2 Trial of OPC-64005 for Major Depressive DisorderMajor Depressive DisorderJPRN-jRCT2080225024Otsuka Pharmaceutical Co., LTD.273
进行中（未招募）
3 期
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)NCT04379635BeiGene453
已完成
不适用
Prospective clinical trial to evaluate efficacy, safety and usability of nanoemulsion cyclosporin 0.05%, emulsion cyclosporin 0.05% and diquafosol 3% in dry eye patientsDiseases of the eye and adnexaKCT0002180The Catholic University of Korea, Yeouido St. Mary's Hospital227
已完成
1 期
Definitive QT Study With MT-8554Healthy VolunteerNCT03471130Tanabe Pharma America, Inc.48